ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto. His group’s research has found that the rate of “migration” of Gleason grade — representing disease progression — was gradual: accounting for no more than a third of patients developing a form of the disease requiring treatment within ten years. The remaining patients can be spared the side effects of treatment.
You may also like...
Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer 21 Jun, 2013 Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer 17 Jan, 2007 Lowering hematocrit below 45 per cent protects against clotting risk in patients with polycythemia vera — randomized study finding 11 Dec, 2012 GAVI Talks: New Funding Mechanisms Make Vaccines Affordable 21 Jun, 2011
- Previous story Low risk prostate cancer: less treatment means lower cost, and better patient outcomes
- Next story Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014